Evaluation of Ocoxin®-Viusid® in Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 13, 2015

Primary Completion Date

January 1, 2018

Study Completion Date

February 19, 2018

Conditions
Breast CancerBreast CarcinomaAdriamycin ToxicityCyclosporine Toxicity
Interventions
COMBINATION_PRODUCT

CT + Ocoxin-Viusid

"The included patients received the Ocoxin-Viusid nutritional supplement at a rate of 75 ml daily (25 ml in 3 doses every 8 hours) administered after main meals diluted in milk or juice. The treatment will start a week before, it will be maintained throughout the coventional chemotherapy treatment\* and up to three weeks after the end of the treatment.~\*All patients should receive the CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles according to protocols provided in the center."

COMBINATION_PRODUCT

CT + Placebo

"The included patients received the OV placebo in oral solution at a rate of 75 ml daily (25 ml in 3 doses every 8 hours), administered after main meals diluted in milk or juice. The treatment will start a week before, it will be maintained throughout the coventional chemotherapy treatment\* and up to three weeks after the end of the treatment.~\*All patients should receive the CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles according to protocols provided in the center."

Trial Locations (1)

10400

National Institute of Oncology and Radiobiology (INOR), La Habana

All Listed Sponsors
lead

Catalysis SL

INDUSTRY

NCT03576521 - Evaluation of Ocoxin®-Viusid® in Breast Cancer | Biotech Hunter | Biotech Hunter